Imugene Ltd (ASX:IMU, OTC:IUGNF) has been given the distinction of presenting at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022) taking place in-person and online from August 6-9, 2022, in Vienna, Austria.
At the conference, the clinical stage immuno-oncology company, will present new data from non-small cell lung cancer patients in the Phase I IMPRINTER trial.
The company will present its findings on August 7, 2022, between 5:00 pm and 7:00 pm CEST and can be found on Imugene’s website at www.imugene.com/conference-presentations following the presentation.
IMU's abstract title is 'Phase 1: IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as Monotherapy or in Combination with Atezolizumab, in Adults with Non-Small Cell Lung Cancer' while the session title is 'Metastatic Non-small Cell Lung Cancer – Immunotherapy'.
The presentation will be given by Professor Michael Boyer MD, MBBS, FRACP, PhD and Chris O’Brien Lifehouse Hospital.
About WCLC 2022
WCLC is the world's largest international gathering of clinicians, researchers and scientists in the field of lung cancer and thoracic oncology.
It is held by the International Association for the Study of Lung Cancer (IASLC), which is a global network of more than 8,000 lung and thoracic cancer specialists from all disciplines dedicated to the study and eradication of lung cancer and other thoracic malignancies. Visit wclc2022.iaslc.org for more information.
About IMU
Imugene is developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Its platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.
IMU’s product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours.
The company aims to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. The company is well funded and resourced, to deliver on its commercial and clinical milestones.